According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on the specific agent and dose) Vomiting (524% of patients) Diarrhea (821% of patients) Constipation (1024% of patients) Abdominal pain or discomfort (514% of patients) These symptoms typically emerge during dose initiation or escalation and often diminish over several weeks as the body adapts
Available at: Office (2025)
When injected subcutaneously, this charge temporarily disrupts the pH balance of the surrounding tissue, triggering a brief localised inflammatory response
3 1 1000-2000
Furthermore, targeted knockdown of GLP-1 Rs in the medial habenula (MHb) or pharmacological antagonism in the interpeduncular nucleus (IPN) increases nicotine consumption and reinstates preference for nicotine-paired environments (Tuesta et al., 2017)
(PubMed) Leonard SW, Bruno RS, Ramakrishnan R, Bray T, Traber MG